Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema ...
Company announcement no. 80Spar Nord annnounces financial guidance for 2025 For 2025, Spar Nord expects core earnings before impairment to the tune of DKK 2,200 – 2,600 million. This guidance is based ...